Articles & insights
EFPIA Code Compliance
Applying the EFPIA Code and national codes to interactions with healthcare professionals, organisations and patient groups.
Entering Phase III? Compliance Expectations Already Have
Why Phase III is when compliance becomes essential for biotech: EFPIA and transparency expectations, early commercial activity and scalable controls.
Read the article 2025-06-12Stakeholder Engagement vs Risk: EFPIA & IFPMA Compliance
Balancing HCP and patient organisation engagement with EFPIA and IFPMA compliance: real-world dilemmas on hospitality and sponsorship.
Read the article 2025-03-19Importance of Bespoke Healthcare Compliance Training for Pharmaceutical Industry
Why pharma compliance training should be bespoke: turning complex EFPIA, IFPMA, ABPI and FSA requirements into practical training for each audience.
Read the articleQuestions, answered
EFPIA Code Compliance: common questions
What is the EFPIA Code of Practice?
It is the collection of ethical rules agreed by EFPIA members for the promotion of medicinal products to healthcare professionals and for interactions with healthcare professionals, healthcare organisations and patient organisations. The current edition is the 2026 EFPIA Code of Practice.
Do companies follow the EFPIA Code directly?
EFPIA’s member associations transpose the EFPIA Code into their national codes, and member companies are bound by the relevant national code in each country. Member associations may adopt stricter standards.
When must transfers of value be disclosed under the EFPIA Code?
Annually, for each full calendar year, within six months of the end of the reporting period. Disclosures must stay public for at least three years and records must be kept for at least five years, unless national law requires otherwise.